Peptide half life sounds like a simple number, but it describes the result of several processes happening at once. Some natural peptide hormones are broken down and cleared within minutes. Other peptide medicines have been deliberately redesigned so that they resist enzymes, bind circulating proteins or leave the body more slowly.
That difference matters when research is compared. A longer half life can mean longer exposure, but it does not automatically mean a stronger effect, a better treatment or a safer compound. The number only makes sense when the molecule, population, route and measurement method are clear.
What does half life actually mean?
Half life is the time taken for the measured concentration of a substance to fall by half during a defined part of its pharmacokinetic profile. In drug development, researchers also look at peak concentration, total exposure, clearance, volume of distribution and how quickly a compound is absorbed.
That is why a single half life figure can be misleading when removed from its study. A value measured after intravenous administration in an animal is not automatically the same as the value after another route in a human. A long apparent half life can also reflect slow absorption as well as slow elimination.
For peptides, the main obstacles are often enzyme breakdown and rapid removal from circulation. Small peptide chains can be vulnerable to proteases and peptidases, while some can also be cleared efficiently through the kidneys. Drug designers can change those properties without changing the basic receptor target.
Natural GLP-1 shows the short life problem
The current FDA label for liraglutide describes native GLP-1 as having a half life of about 1.5 to 2 minutes because it is rapidly degraded by enzymes including DPP-4 and neutral endopeptidases. Regulator approved indication 1
That short persistence is useful physiology. A natural signal can rise and then be switched off quickly. It is less convenient when the goal is to create a medicine that maintains receptor activity for much longer.
Liraglutide is one example of how molecular design changes that behaviour. The same FDA label reports an elimination half life of about 13 hours and explains that self association, plasma protein binding and resistance to enzymatic degradation all contribute to its longer pharmacokinetic profile. Regulator approved indication 1
Albumin can act as a circulating partner
Albumin is an abundant protein in blood with a much longer residence time than most small peptides. One way to extend peptide exposure is to design a molecule that binds albumin strongly. The albumin bound fraction is less available for rapid renal filtration and can also be less exposed to some degrading enzymes. Mechanistic
This principle is used by several peptide medicines. Semaglutide carries a fatty diacid modification that promotes albumin binding. The current FDA Wegovy label states that semaglutide is more than 99% bound to plasma albumin, which decreases renal clearance and protects it from degradation. Its elimination half life is about one week. Regulator approved indication 2
Tirzepatide uses a related idea. Its current FDA label describes a fatty diacid attached to the peptide that enables albumin binding and prolongs half life. The label reports a half life of about five days. Regulator approved indication 3
The exact chemistry differs between molecules. The useful point is that albumin binding can change how a peptide moves through the body without changing the fact that the active part is still a peptide.
What does the laboratory evidence show?
The albumin mechanism is not inferred only from product labels. It has been measured directly.
In an in vitro study using human plasma, more than 98.9% of liraglutide was protein bound at the tested clinically relevant concentration. Binding measured against purified human serum albumin was 99.4%. In vitro 4
This is useful mechanistic evidence, but it is still an in vitro experiment. It shows that liraglutide binds strongly to plasma proteins under the study conditions. It does not by itself establish how long the medicine remains active in a person or what clinical outcome follows. Those questions need human pharmacokinetic and clinical data.
Animal development studies answer a different question
The discovery programme for semaglutide tested changes intended to increase albumin affinity and resistance to metabolic breakdown. In the published development paper, semaglutide had a plasma half life of 46.1 hours after intravenous administration in mini pigs, with a mean residence time of 63.6 hours after subcutaneous administration. Animal 5
Those animal measurements helped researchers select a candidate for human development. They should not be substituted for the human value. The current FDA label, based on the clinical development programme, gives semaglutide an elimination half life of about one week in people. Regulator approved indication 2
The comparison shows why evidence type matters. Animal pharmacokinetics can guide drug design, while human pharmacokinetics determines what is actually observed in people.
CJC-1295 shows another route to a long half life
Not every long acting peptide uses the same fatty acid design. CJC-1295 with its drug affinity complex was engineered to bind albumin after entering the circulation. Animal 6
Two randomised placebo controlled studies in healthy adults aged 21 to 61 examined CJC-1295 over 28 and 49 days. The estimated half life was 5.8 to 8.1 days. The studies also found sustained increases in growth hormone for six days or more and IGF-1 for 9 to 11 days after a single administration. Human 7
That is human pharmacokinetic and hormone evidence. It is not proof of muscle gain, fat loss, recovery or any other clinical outcome. The study was designed to measure pharmacokinetics and hormone responses, so those are the claims its data can support.
This is also why the exact molecule matters. A half life measured for an albumin binding construct should not be transferred to a related peptide that lacks the same modification.
Why enzyme resistance matters
Albumin binding is only one strategy. Peptide sequences can also be altered so that common enzymes no longer recognise or cut them as easily.
The semaglutide development paper describes an amino acid substitution designed to improve stability against DPP-4, while the FDA label identifies both albumin binding and protection from degradation as important parts of its prolonged profile. Mechanistic 5 2
Liraglutide also resists degradation more effectively than native GLP-1. Its FDA label links its 13 hour half life to a combination of delayed absorption, plasma protein binding and metabolic stability. Regulator approved indication 1
The important point is that half life usually comes from a package of properties. Changing one amino acid, adding a lipid chain, increasing protein binding or altering absorption can each change the final pharmacokinetic profile.
Half life is not the same as duration of effect
A peptide can remain measurable after its strongest biological effect has faded, or its downstream effects can persist after blood concentrations have fallen. Receptor binding, active metabolites, target biology and the shape of the concentration curve all matter.
That is why comparing peptides by half life alone can produce the wrong conclusion. A five day value is not automatically better than a 13 hour value. It simply describes a different exposure profile.
The same caution applies to safety. Longer persistence means that exposure lasts longer, but half life alone does not tell you whether a compound is safe. Safety comes from toxicology, controlled human trials, adverse event data and regulator review for the exact product and population.
Why the route and study design matter
Pharmacokinetic numbers depend on how and where they were measured. Intravenous administration removes the absorption step. Other routes add an absorption phase that can affect the apparent concentration curve. Species, age, kidney function, body size and formulation can also change exposure.
For that reason, the best source for a medicine's clinical half life is usually the regulator reviewed prescribing information, supported by the underlying human pharmacology studies. Discovery papers remain useful for explaining how the molecule was engineered, but their animal or in vitro numbers should stay labelled as such.
Semaglutide
High-quality evidenceMetabolic & incretin · 6 cited studies
Multiple large, replicated, placebo controlled randomised outcome trials with hard endpoints across diabetes, obesity, cardiovascular disease, kidney disease and liver disease, all independently verified against PubMed and ClinicalTrials.gov, supported by approved regulatory labelling in the US, UK and EU.
UK status. Licensed by the MHRA for type 2 diabetes and, at the 2.4 mg weekly dose, for weight management alongside diet and physical activity.
Liraglutide
High-quality evidenceMetabolic & incretin · 3 cited studies
A completed and published cardiovascular outcome trial in over 9,000 people plus multiple large randomised placebo controlled weight management trials, all three citations independently verified against PubMed and their registry records, supported by more than a decade of approved regulatory labelling in the US, UK and EU.
UK status. Licensed by the MHRA for type 2 diabetes and, at 3.0 mg daily, for weight management alongside a reduced calorie diet and increased physical activity.
Tirzepatide
High-quality evidenceMetabolic & incretin · 6 cited studies
Multiple large randomised placebo controlled phase 3 trials with head to head active comparators, plus outcome trials in sleep apnoea and heart failure, with all four peer reviewed citations independently verified against PubMed and ClinicalTrials.gov, and approved regulatory labelling in the US, UK and EU.
UK status. Licensed by the MHRA for type 2 diabetes and for weight management alongside a reduced calorie diet and increased physical activity.
CJC-1295 with DAC
Limited evidenceGH secretagogues · 3 cited studies
Human data consist of two small, short, sponsor run pharmacodynamic studies in healthy volunteers measuring only growth hormone and IGF-1; the only other citation is a mouse study, no efficacy trial has ever been completed or published, and the single phase 2 trial was halted and never reported.
UK status. No UK marketing authorisation.
The BioRx conclusion
Peptide half life is a pharmacokinetic measurement, not a score of quality. Natural peptides can disappear quickly because enzymes and clearance systems are built to switch off biological signals. Engineered peptides can last much longer when their sequence, protein binding or other molecular properties are changed.
Semaglutide, liraglutide, tirzepatide and CJC-1295 show several ways that persistence can be extended. Their numbers are not interchangeable, and neither are the evidence types behind them. Human label data, human experimental studies, animal development work and in vitro binding experiments each answer different questions.
For the broader biology, see What Are Peptides?. For how peptide molecules are assembled and where impurities can arise, see How Peptides Are Actually Made.
Frequently asked questions
What is peptide half life?
It is the time taken for the measured concentration of a peptide to fall by half during a defined part of its pharmacokinetic profile.
Why do some peptides last only minutes?
Natural peptides can be rapidly broken down by enzymes and cleared from circulation. Native GLP-1 is one example, with the FDA liraglutide label describing a half life of about 1.5 to 2 minutes.
How can a peptide be made to last longer?
Drug developers can increase resistance to degrading enzymes, promote binding to long lived blood proteins such as albumin, change molecular size or alter absorption and clearance characteristics.
Does a longer half life mean a peptide works better?
No. Half life describes exposure over time. Clinical benefit has to be shown in trials measuring the outcome of interest.
Can animal half life data be used as a human value?
No. Animal pharmacokinetics can guide development, but species and study conditions matter. Human values should come from human studies or regulator reviewed clinical data.
References
Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.
- FDA, Victoza prescribing information, 2025
- FDA, Wegovy prescribing information, 2025
- FDA, Mounjaro prescribing information, 2025
- Plum et al, Journal of Pharmaceutical Sciences 2013, PMID 23853127
- PubMed, PMID 26308095
- Jette et al, Endocrinology 2005, PMID 15817669
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism.PubMed · DOI · View study in BioRx
